X0609 4 2026-06-22 0001724521 Arcus Biosciences, Inc. RCUS 0001422996 Jaen Juan C. false C/O ARCUS BIOSCIENCES, INC. 3928 POINT EDEN WAY HAYWARD CA 94545 true President true Common Stock 2026-06-22 4 S 0 9236 27.0313 D 913004 I By Trust Common Stock 2026-06-23 4 S 0 14067 27.6875 D 898937 I By Trust Common Stock 2026-06-23 4 S 0 1697 28.0612 D 897240 I By Trust Common Stock 2026-06-24 4 S 0 6431 29.6595 D 890809 I By Trust Common Stock 378291 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.01 to $28.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.0050 to $28.1550, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $29.8050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Includes the unvested portion of the Reporting Person's RSU grants. Includes 1,279 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan. /s/ Carolyn Tang, Attorney-in-Fact 2026-06-24